{
    "nctId": "NCT00524459",
    "briefTitle": "Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery",
    "officialTitle": "Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 6,
    "primaryOutcomeMeasure": "Pathological Complete Response",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer using core biopsies\n\n  * Locally advanced disease\n  * Resectable disease\n  * Fine needle aspiration cytology allowed and must demonstrate invasive adenocarcinoma\n* No more than 8 weeks since initial cytologic or histologic diagnosis of breast cancer\n* Tumor must meet the following criteria:\n\n  * Palpable on clinical examination and confined to either the breast or to the breast and ipsilateral axilla\n  * Measured clinically as greater than 2 cm in size (T2)\n* Patients with skeletal pain are eligible if bone scan and/or roentgenological examination fail to disclose metastatic disease\n\n  * Suspicious findings must be confirmed as benign by x-ray, MRI scan, or biopsy\n* Hormonal status not specified\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* Female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 10 years\n* Platelet count \u2265 100,000/mm\u00b3\n* ANC \u2265 1,500/mm\u00b3\n* Hemoglobin \u2265 9.0 g/dL\n* Bilirubin normal\n* AST or ALT normal\n* Alkaline phosphatase normal\n* Serum creatinine normal\n* Negative pregnancy test\n* Fertile patients must use effective contraception (e.g., abstinence, intrauterine device, barrier device with spermicide, or surgical sterilization) during and for 3 months after completion of study therapy\n* Normal cardiac function by LVEF or MUGA scan\n* Patients with prior non-breast malignancies are eligible if they have been disease-free for \u2265 10 years\n\n  * The following are allowed even if diagnosed within the past 10 years:\n\n    * Squamous or basal cell carcinoma of the skin that has been effectively treated\n    * Carcinoma in situ of the cervix that has been treated by operation only\n    * Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by segmental resection only\n\nExclusion criteria:\n\n* Pregnant or lactating women\n* Male patients\n* Hyperbilirubinemia\n* Female patients with 1 or more of the following conditions:\n\n  * Ulceration, erythema, infiltration of the skin (complete fixation), or peau d'orange (edema) of any magnitude\n\n    * Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration\n  * Ipsilateral lymph nodes that are clinically fixed to one another or to other structures (N2 disease)\n  * Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant\n  * Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless there is biopsy evidence that these are not involved with the tumor\n* Nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy\n* Active cardiac disease that would preclude the use of doxorubicin hydrochloride, including any of the following:\n\n  * Documented myocardial infarction\n  * Angina pectoris that requires the use of antianginal medication\n  * History of documented New York Heart Association class II-IV heart failure\n  * Valvular disease with documented cardiac function compromise\n  * Poorly controlled hypertension (i.e., diastolic BP \\> 100 mm Hg)\n\n    * Patients with well-controlled hypertension and on medication are eligible for study\n* Psychiatric or addictive disorders that would preclude obtaining informed consent\n\nPRIOR CONCURRENT THERAPY:\n\nInclusion criteria:\n\n* Concurrent noncancer therapies allowed if used for conditions other than breast cancer\n* Adjuvant therapy after surgery allowed\n\nExclusion criteria:\n\n* Prior radiotherapy, chemotherapy, immunotherapy, and/or hormonal therapy for breast cancer\n* Prior anthracycline therapy for any condition\n* Concurrent hormonal therapy including tamoxifen, aromatase inhibitors, or raloxifene\n* Concurrent sex hormonal therapy including birth-control pills or ovarian hormonal replacement therapy\n* Concurrent other cancer therapy\n* Concurrent herbal or alternative therapies for breast cancer",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT"
}